Hardy, Susan E · The American journal of geriatric pharmacotherapy · 2009 · DOI
This review looked at whether a stimulant medication called methylphenidate (Ritalin) can help treat fatigue, depression, and apathy in older adults and very ill patients. Researchers searched medical databases for studies testing this medication. While the medication appeared to be safe and tolerable, the studies weren't strong enough to prove it actually works well for these symptoms.
While this review excluded chronic fatigue syndrome by design, it is relevant to ME/CFS research because fatigue and apathy are core ME/CFS symptoms that significantly impact quality of life. Understanding whether stimulant medications can effectively treat these symptoms—and at what safety cost—informs treatment approaches for patients with ME/CFS who experience similar debilitating fatigue.
This review does not establish that methylphenidate is effective for fatigue in ME/CFS specifically, as chronic fatigue syndrome was explicitly excluded from the analysis. The conflicting results and poor methodology across trials mean no causal relationship between methylphenidate and symptom improvement can be definitively established. Tolerability in older, medically ill populations may not generalize to ME/CFS patients, who often have different disease mechanisms and medication sensitivities.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →